A $200 Million Injection From the U.S. Will Allow Aspen to Produce More Johnson & Johnson COVID-19 Vaccines for Africa
With just 1.5% of its 1.3 billion people fully vaccinated, Africa is the least protected continent in the world against the coronavirus.
But the U.S. is stepping up to help address the shortfall. With a $200 million investment in an Aspen Pharmacare manufacturing facility in South Africa, the U.S. is trying to pave the way for increased production of COVID-19 vaccines.
The investment will allow the plant to expand its capacity beyond its current rate of 300 million doses per year, according to News24.
Aspen, the largest pharmaceutical company in Africa, produces the Johnson & Johnson vaccine in the port city of Gqeberha, formerly Port Elizabeth, in South Africa’s Eastern Cape. J&J and Aspen revealed their vaccine partnership in November of last year.
Photo courtesy of Daniel Schludi.
- Health Care